Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cam2020 M2SR H3N2 Vaccine in Older Adults
NCT05163847Phase 1Completed
- Sponsor
- FluGen
- Start
- Jun 2022
- Primary completion
- Nov 2022
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of M2SR H3N2 influenza vaccine in influenza (4 arms), sponsored by FluGen. Primary endpoints: Solicited Adverse Events, Unsolicited Adverse Events and 1 more. Started Jun 2022; status: completed.
02
Drugs
M2SR H3N2 influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05163847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163847.